Description
Introduction:
Nivolumab is a genetically engineered anti-PD-1 mAb that binds to PD-1 with high affinity and blocks its interactions with both PD-L1 and PD-L2, thereby stimulates memory response to tumor antigen-specific T cell proliferation. It is a prescription medicine used in combination with ipilimumab as a first treatment for adults with a non-small cell lung cancer that are positive for PD-L1, but do not have an abnormal EGFR or ALK gene. Anti-Drug Antibodies (ADA) may induce unwanted side effects in biopharmaceuticals. Hence, ADA has been subjected to increase in scrutiny by the regulatory authorities using immunogenicity safety studies. ADA has been observed in pre-clinical and clinical studies, resulting in significant changes in toxicology, pharmacokinetics and efficacy. These effects result from the generation of drug-induced (neutralizing) autoantibodies against Trastuzumab and can be responsible for allergic reaction, or even anaphylactic shock. This ELISA kit detects Anti-Nivolumab antibodies and may be used for monitoring immunogenicity.
Intended Use:
The KRIBIOLISA Anti-Nivolumab ELISA is used as an analytical tool for quantitative determination of Anti-Nivolumab antibodies in human serum and plasma.
Principle:
The method employs the sandwich enzyme immunoassay technique. Nivolumab is pre-coated onto microwells. Samples or standards are pipetted into microwells and antibodies to Nivolumab present in the standards or sample are bound by the capture antibody. Then, a HRP (horseradish peroxidase) conjugated Nivolumab is pipetted and incubated. After washing microwells in order to remove any nonspecific binding, the ready to use substrate solution (TMB) is added to microwells and color develops proportionally to the amount of AntiNivolumab in the sample. Color development is then stopped by addition of stop solution. Absorbance is measured at 450 nm
If you have published a paper by using any of our ELISA since 01/01/2023, kindly fill out the “Krishgen Publication Reward Application Form” with complete information and send it by at email: info@krishgen.com, with the subject “Krishgen Publication Reward”. We will get back to you with the Amazon / Krishgen Credit Reward after we confirm it ASAP!